# Surgery Partners, Inc. (SGRY) Stock Analysis: Exploring a 53.87% Upside Potential

- Link: https://www.directorstalkinterviews.com/surgery-partners-inc-sgry-stock-analysis-exploring-a-53-87-upside-potential/4121229693
- Published: 2025-12-09T11:31:37+00:00
- Author: Madison Wilson

Surgery Partners, Inc. (NASDAQ: SGRY) operates within the healthcare sector, specializing
in medical care facilities across the United States. With a market capitalization
of approximately $2.16 billion, the company provides a comprehensive network of 
surgical facilities and ancillary services, offering a variety of non-emergency 
surgical procedures. This diverse portfolio positions Surgery Partners as a significant
player in the medical care facilities industry, catering to specialties such as 
orthopedics, ophthalmology, and gastroenterology.

SGRY’s current stock price of $16.72 reflects a slight decline of 0.03% from its
previous session, fluctuating within a 52-week range of $15.06 to $25.87. This places
the stock at an interesting juncture, especially given its potential upside of 53.87%,
as suggested by the average analyst target price of $25.73. It’s noteworthy that
the stock is trading below both its 50-day and 200-day moving averages, which stand
at $19.22 and $21.74, respectively. The Relative Strength Index (RSI) at 39.90 indicates
that SGRY is nearing oversold conditions, potentially presenting a buying opportunity
for investors looking to capitalize on undervalued stocks.

Despite trading at a forward P/E ratio of 24.29, the company does not currently 
have trailing P/E, PEG, or price-to-book ratios available. This absence of traditional
valuation metrics may be attributed to its negative earnings per share (EPS) of -
1.36 and a return on equity (ROE) of just 0.66%. These figures underscore the challenges
SGRY faces in achieving profitability, yet the company demonstrates robust revenue
growth of 6.60%, coupled with a healthy free cash flow of approximately $131.26 
million.

From an analyst perspective, Surgery Partners enjoys considerable support, with 
9 buy ratings and 3 hold ratings, and no sell ratings. The bullish sentiment is 
further emphasized by the target price range of $18.00 to $33.00, suggesting significant
potential for upward movement. The absence of a dividend yield indicates that the
company is likely reinvesting earnings to fuel growth and expansion rather than 
returning capital to shareholders.

Technical indicators show a MACD of -0.66 and a signal line of -0.90, suggesting
that SGRY is currently in a bearish trend. However, these technical patterns can
shift rapidly, especially given the positive analyst outlook and the company’s strategic
focus on expanding its surgical and ancillary services network.

Investors considering Surgery Partners should weigh the company’s growth potential
against its current financial challenges. The healthcare sector’s stability, combined
with SGRY’s strategic positioning in non-emergency surgical procedures, presents
a compelling case for long-term value creation. As the company continues to navigate
the complexities of the healthcare landscape, its ability to enhance profitability
and leverage its free cash flow will be critical to unlocking shareholder value.

Share on:
